Legal status of recreational cannabis and self-reported substitution of cannabis for opioids or prescription pain medication in Canada and the United States [0.03%]
加拿大和美国娱乐性大麻的法律地位及其与处方止痛药或阿片类药物的自我报告替代关系
Elle Wadsworth,Lindsey A Hines,David Hammond
Elle Wadsworth
Aims: With increased liberalization of cannabis policies in North America, there is growing interest in the use of cannabis to manage pain instead of opioids. The objectives of the study were to (1) examine the use of cannabis for pain reli...
Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons [0.03%]
opioid使用障碍在州监狱中的药物治疗：曾经服刑人员的视角
Peter C Treitler,Michael Enich,Donald Reeves et al.
Peter C Treitler et al.
Background: Opioid use disorder (OUD) is common among incarcerated persons and risk of overdose and other adverse drug-related consequences is high after release. Recognizing their potential to reduce these risks, some correctional systems ...
Factors associated with binge drinking-Findings from 2019 Kansas behavioral risk factor surveillance system [0.03%]
与醉酒相关的因素——来自2019年堪萨斯州行为危险因素监测系统的结果分析
Shannon R Lines,Aliya Marroquin,Steve Corbett et al.
Shannon R Lines et al.
Background: In the U.S., excessive drinking accounts for one in 10 deaths among adults aged 20-64 years old. Binge drinking is a common form of excessive alcohol consumption that contributes to this chilling statistic. Binge drinking is def...
Using data science to improve outcomes for persons with opioid use disorder [0.03%]
利用数据科学改善阿片类药物使用障碍患者的治疗效果
Corey J Hayes,Michael A Cucciare,Bradley C Martin et al.
Corey J Hayes et al.
Medication treatment for opioid use disorder (MOUD) is an effective evidence-based therapy for decreasing opioid-related adverse outcomes. Effective strategies for retaining persons on MOUD, an essential step to improving outcomes, are need...
Evaluation of U.S. state opioid prescribing restrictions using patient opioid consumption patterns from a single, urban, academic institution [0.03%]
基于一家城市学术机构的患者阿片类药物消耗模式对美国各州阿片类药房规定进行评估
Kortney A Robinson,Jayson S Marwaha,Chris J Kennedy et al.
Kortney A Robinson et al.
Background: Since 2017, states, insurers, and pharmacies have placed blanket limits on the duration and quantity of opioid prescriptions. In many states, overlapping duration and daily dose limits yield maximum prescription limits of 150-35...
Cervical cancer screening, abnormal results, and follow-up in women with substance use-related diagnoses [0.03%]
与物质使用相关诊断的妇女的宫颈癌筛查、异常结果及随访
McKenna C Eastment,Ayushi Gupta,Jocelyn James et al.
McKenna C Eastment et al.
Background: Substance use-related diagnoses are common and associated with poor health outcomes. The objective of this analysis was to compare rates of cervical cancer screening, screening abnormalities, and follow-up care in women with and...
Clinical documentation of patient-reported medical cannabis use in primary care: Toward scalable extraction using natural language processing methods [0.03%]
自然语言处理方法在全科医疗中提取患者自报的大麻用药情况的临床记录研究
David S Carrell,David J Cronkite,Mary Shea et al.
David S Carrell et al.
Background: Most states have legalized medical cannabis, yet little is known about how medical cannabis use is documented in patients' electronic health records (EHRs). We used natural language processing (NLP) to calculate the prevalence o...
Rates of discontinuation and non-publication of trials for the pharmacologic treatment of alcohol use disorder [0.03%]
酒精使用障碍的药物治疗试验中止和未发表率
Micah Hartwell,Nicholas B Sajjadi,Samuel Shepard et al.
Micah Hartwell et al.
Objective: With approximately 15 million individuals in the United States meeting criteria for Alcohol Use Disorder (AUD), advancing effective medication-assisted treatment options is crucial. This advancement stems from the publication of ...
Satisfaction with group-based appointments among patients with opioid use disorder in an urban buprenorphine clinic [0.03%]
城市苯二氮卓类戒瘾门诊中阿片类药物使用障碍患者的分组预约满意度
Serra Akyar,Amesika Nyaku,Kristyn Lao et al.
Serra Akyar et al.
Background: Successful implementation of group-based appointments can increase capacity to treat patients, reduce costs, and improve productivity. We sought to understand the acceptability of group-based appointments for opioid use disorder...
Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies [0.03%]
扩大社区药房纳洛酮、布痛尼色和非处方注射器供应的随机对照试验（Respond to Prevent研究）：研究方案
Traci C Green,Jeffrey Bratberg,Adriane N Irwin et al.
Traci C Green et al.
Access to the opioid antidote naloxone is a critical component of addressing the opioid crisis. Naloxone is a population-level prevention intervention associated with substantial reductions in overdose mortality and reduction of nonfatal ov...